S100A12 Gene Linked To Cancer, Neurodegenerative Diseases (G6283)

Target Name: S100A12

NCBI ID: G6283

S100A12

S100A12 Gene Linked To Cancer, Neurodegenerative Diseases

S100A12 (CAGC), or cytosine-guanine dinucleotide synthase, is a protein that is expressed in various tissues throughout the body. It is a key enzyme in the DNA replication process, which is essential for the growth and development of all living organisms. The S100A12 gene has been identified as a potential drug target (or biomarker) due to its involvement in the development and progression of various diseases, including cancer.

The S100A12 gene was first identified in the late 1990s as a potential cancer-related gene. It is located on chromosome 1p36 and has been shown to be involved in the regulation of cell cycle progression, apoptosis (programmed cell death), and DNA replication. S100A12 has also been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

S100A12 has been shown to be involved in the development and progression of various diseases, including cancer. For example, studies have shown that high levels of S100A12 are associated with poor prognosis in patients with pancreatic cancer, a highly aggressive form of cancer that is characterized by the formation of tumors that infiltrate the surrounding tissue and have the ability to spread to other parts of the body.

In addition to its involvement in cancer, S100A12 has also been shown to be involved in the development of neurodegenerative diseases. For example, studies have shown that S100A12 is involved in the development and progression of Alzheimer's disease, a neurodegenerative disorder that is characterized by the accumulation of toxic protein aggregates in the brain. Similarly, S100A12 has also been shown to be involved in the development and progression of Parkinson's disease, a neurodegenerative disorder that is characterized by the loss of motor and cognitive function.

S100A12 is also involved in the regulation of cell cycle progression and apoptosis. Studies have shown that S100A12 plays a role in the regulation of cell cycle progression by preventing the entry of cells into the G1 phase of the cell cycle. This is important for the regulation of cell growth and for the development of cancer. Similarly, S100A12 has also been shown to play a role in the regulation of apoptosis by preventing the formation of cell death pathways.

In conclusion, S100A12 is a protein that is involved in the regulation of cell cycle progression, apoptosis, and DNA replication. Studies have shown that high levels of S100A12 are associated with the development and progression of various diseases, including cancer and neurodegenerative disorders. As a result, S100A12 is a potential drug target (or biomarker) that could be targeted with small molecules or other therapeutic agents to treat these diseases. Further research is needed to fully understand the role of S100A12 in the development and progression of disease and to develop effective treatments.

Protein Name: S100 Calcium Binding Protein A12

Functions: S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its pro-inflammatory activity involves recruitment of leukocytes, promotion of cytokine and chemokine production, and regulation of leukocyte adhesion and migration. Acts as an alarmin or a danger associated molecular pattern (DAMP) molecule and stimulates innate immune cells via binding to receptor for advanced glycation endproducts (AGER). Binding to AGER activates the MAP-kinase and NF-kappa-B signaling pathways leading to production of pro-inflammatory cytokines and up-regulation of cell adhesion molecules ICAM1 and VCAM1. Acts as a monocyte and mast cell chemoattractant. Can stimulate mast cell degranulation and activation which generates chemokines, histamine and cytokines inducing further leukocyte recruitment to the sites of inflammation. Can inhibit the activity of matrix metalloproteinases; MMP2, MMP3 and MMP9 by chelating Zn(2+) from their active sites. Possesses filariacidal and filariastatic activity. Calcitermin possesses antifungal activity against C.albicans and is also active against E.coli and P.aeruginosa but not L.monocytogenes and S.aureus

The "S100A12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S100A12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets